TG Therapeutics (TGTX) Q4 2024: BRIUMVI U.S. Revenue Surges 250%, Pivotal Subcutaneous Trial Set for Mid-2025
TG Therapeutics delivered robust commercial momentum with BRIUMVI U.S. net revenues growing 250% year over year, supported by expanding physician adoption and strong patient demand. The company is advancing key clinical programs, including a pivotal subcutaneous (sub-Q) BRIUMVI trial anticipated to launch mid-2025, positioning for broader market penetration. Financial discipline and pipeline expansion underpin confidence in exceeding 2025 revenue guidance amid a competitive multiple sclerosis (MS) landscape.
Summary
- Physician Adoption Accelerates: Increasing market share driven by strong real-world data and enhanced infusion regimens.
- Pipeline Expansion Progress: Pivotal subcutaneous BRIUMVI trial and novel CAR T-cell therapy entering clinical stages.
- Financial Discipline Supports Growth: Controlled operating expenses and solid cash position enable continued investment.
Business Overview
TG Therapeutics is a commercial-stage biopharmaceutical company focused on therapies targeting B-cell diseases, primarily multiple sclerosis and autoimmune disorders. The company generates revenue principally through sales of BRIUMVI, a glycoengineered anti-CD20 monoclonal antibody indicated for relapsing forms of MS, with commercial operations in the U.S. and Europe. Its pipeline includes clinical programs exploring subcutaneous formulations and allogeneic CD19 CAR T-cell therapies for autoimmune diseases.
Performance Analysis
In the fourth quarter of 2024, TG Therapeutics reported U.S. net product revenue for BRIUMVI of $103.6 million, representing an approximately 250% increase year over year and 24% sequential growth. Full-year 2024 global revenue reached approximately $329 million, including $310 million from U.S. BRIUMVI sales and milestone payments from ex-U.S. commercialization partners. This performance notably exceeded management’s initial guidance and reflects strong market uptake.
Operating expenses remained well-managed, with full-year 2024 operating expenses excluding non-cash compensation totaling $206 million, below the guided range. The company achieved GAAP net income of $23.4 million for the year, marking a significant turnaround from prior periods. Cash, cash equivalents, and investments stood at $311 million at year-end, providing a solid liquidity base to support ongoing commercialization and R&D activities.
- Revenue Growth Drivers: Broad-based customer enrollment, with academic hospitals increasingly contributing to growth.
- Margin Considerations: Gross margin impacted in Q4 by lower-margin product sales to ex-U.S. partner NeuroXpharm, an infrequent event.
- Expense Discipline: Controlled SG&A and R&D spending despite expanding commercial infrastructure and pipeline development.
This financial and operational footing positions TG Therapeutics to capitalize on market opportunities and advance its clinical programs into pivotal stages.
Executive Commentary
"2024 was a year of significant outperformance and growth for TG, highlighted by the strong adoption of BRIUMVI for adult patients with relapsing forms of multiple sclerosis, which surpassed our initial expectations... These accomplishments provide a solid foundation as we look toward continued success in 2025."
Michael S. Weiss, Chairman and Chief Executive Officer
"We are pleased to report U.S. pre-MV net product revenue of $103.6 million during the fourth quarter... Operating expenses have remained well-controlled and below our guided ranges... Our existing cash provides us with a strong financial position to continue to support the BRIUMVI commercialization and invest in our research and development efforts."
Sean Power, Chief Financial Officer
Strategic Positioning
1. Expanding BRIUMVI Market Penetration Through Real-World Data and Enhanced Infusion Regimens
TG Therapeutics leverages compelling five-year clinical data demonstrating sustained efficacy and safety of BRIUMVI, with 92% of patients free from disability progression and an annualized relapse rate of 0.02 in year five. Real-world evidence from over 160 patients further supports its differentiated profile, including mitigation of wearing-off effects seen with competitor therapies. The company is advancing enhanced intravenous infusion protocols, including a 30-minute infusion and a consolidated introductory dosing regimen, to improve patient convenience and adoption.
2. Pivotal Subcutaneous BRIUMVI Trial Targeted for Mid-2025 Launch
Recognizing the shift in MS treatment preferences toward self-administered subcutaneous therapies, TG is developing a sub-Q formulation of BRIUMVI with promising bioavailability data supporting dosing intervals potentially twice as long as current monthly options. The planned pivotal Phase 3 trial, expected to enroll approximately 125 to 150 patients per arm, aims to validate this regimen and expand market reach, particularly capturing nearly 40% of new MS patients who prefer subcutaneous administration.
3. Pipeline Diversification with Allogeneic CD19 CAR T Therapy
TG’s license agreement with Precision BioSciences enables development of azercabtagene zapreleucel (azer-cel), an off-the-shelf allogeneic CAR T-cell therapy targeting CD19 for autoimmune diseases. The Phase 1 dose-finding study recently received IND clearance and is poised to enroll patients with progressive forms of MS. This program represents a potential first-in-class therapeutic addressing unmet needs in refractory autoimmune disorders.
4. International Expansion via Partnered Commercialization
BRIUMVI’s launch in Europe through partner Neuraxpharm has extended the company’s geographic footprint, with availability in Germany, several EU countries, and the UK. Positive feedback from these markets complements U.S. growth and contributes milestone payments, supporting global revenue diversification.
5. Financial Discipline Supports Sustainable Growth
Management maintains a disciplined approach to operating expenses, guiding 2025 operating expenses excluding non-cash compensation to approximately $300 million, up from $206 million in 2024 but aligned with planned commercial and clinical expansion. The strong cash position and positive operating cash flow trends underpin confidence in funding ongoing development and commercialization without near-term capital raises.
Key Considerations
TG Therapeutics’ 2024 performance illustrates the successful transition from development to commercial execution, yet several factors warrant close investor attention:
- Market Penetration Dynamics: Continued adoption depends on expanding presence in academic and community infusion centers and overcoming competition from established anti-CD20 therapies.
- Regulatory and Label Expansion: The timing and outcome of pivotal trials for subcutaneous BRIUMVI and enhanced infusion regimens will be critical for label updates and broader patient access.
- Pipeline Execution Risk: Early-stage programs, including the allogeneic CAR T study, face inherent clinical and enrollment uncertainties that could impact timelines and capital allocation.
- Gross-to-Net Variability: The company expects gross-to-net revenue adjustments in the 70% to 75% range, with potential quarter-to-quarter fluctuations affecting net sales visibility.
- Competitive Landscape: New entrants and high-dose formulations from competitors may pressure market share, requiring ongoing differentiation and physician engagement.
Risks
Risks include potential delays or failures in clinical trial execution, regulatory setbacks, and competitive pressures from other MS therapies, particularly high-dose anti-CD20 agents. Additionally, reimbursement challenges and changes in payer coverage could impact patient access and revenue growth. The company’s reliance on third-party manufacturing and partners for ex-U.S. commercialization adds operational complexity. Investors should also monitor the pace of enrollment and data readouts from early-stage pipeline programs, which remain uncertain.
Forward Outlook
For the first quarter of 2025, TG Therapeutics anticipates U.S. BRIUMVI net revenue of approximately $115 million, reflecting robust early-year demand. Full-year 2025 guidance targets total global revenue near $540 million, including $525 million from U.S. BRIUMVI sales. Operating expenses excluding non-cash compensation are projected at roughly $300 million, reflecting controlled investment in commercial and clinical activities. Management expects to initiate pivotal subcutaneous BRIUMVI trials by mid-year and advance multiple pipeline studies, including enrollment in the CAR T-cell program for progressive MS.
- Q1 2025 U.S. BRIUMVI net revenue: ~$115 million
- Full-year 2025 total global revenue target: ~$540 million
- 2025 operating expenses (ex. non-cash): ~$300 million
Takeaways
TG Therapeutics has demonstrated strong commercial traction with BRIUMVI, driven by compelling long-term clinical data and strategic initiatives to enhance patient experience. The upcoming pivotal subcutaneous trial represents a critical inflection point to capture a growing segment of the MS market favoring self-administered therapies. Financial discipline and a growing cash position provide a foundation to support both commercialization and pipeline advancement. Investors should monitor clinical trial progress, competitive dynamics, and regulatory developments as key determinants of sustained growth potential.
- Commercial Momentum Validates Strategy: Rapid revenue growth and increasing market share reflect successful physician engagement and patient adoption.
- Pipeline Catalysts Loom: Pivotal subcutaneous trial and CAR T-cell program progress will be material drivers for future value creation.
- Execution and Competition Remain Key: Maintaining expense discipline while navigating competitive pressures will be essential to sustaining growth.
Conclusion
TG Therapeutics’ fourth quarter and full year 2024 results underscore a successful commercial launch of BRIUMVI and meaningful pipeline progress. Robust revenue growth, coupled with disciplined spending and a strong cash balance, positions the company well for 2025. The forthcoming pivotal subcutaneous BRIUMVI trial and early-stage CAR T-cell program represent significant strategic initiatives that could broaden therapeutic options and market reach in autoimmune diseases.
Industry Read-Through
TG Therapeutics’ performance highlights evolving trends in the multiple sclerosis treatment landscape, including the growing importance of patient convenience through subcutaneous administration and the expanding role of B-cell targeted therapies. The company’s advancement of allogeneic CAR T-cell therapies for autoimmune diseases signals broader industry interest in cell-based immunomodulation beyond oncology. Competitors and investors should watch the outcomes of pivotal subcutaneous trials and real-world adoption patterns, as these will shape competitive positioning and market dynamics across the MS and autoimmune sectors.